VBVladimir D. Beketov

Vladimir D. Beketov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vladimir D. Beketov has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of digital educational platforms on cognitive development and emotional well-being

    by Vladimir Beketov, Marina Taranova, Marina Lebedeva

    This study aimed to identify psychophysiological markers that shape students’ cognitive–emotional trajectories during learning with Moodle 3.9, supplemented by Canvas learning management system (LMS) for video delivery and Kahoot for game-based assessments. The experiment involved 124 undergraduate students and spanned 16 weeks with five measurement points: the experimental group studied using digital platforms, while the control group followed a traditional format. The methodology incorporated Raven’s, Stroop, and N-back cognitive tests; measurements of heart rate, skin conductance, and cortisol levels; facial expression analysis; and learning-platform data. Working memory improved by 2.2 points with an effect size of d=2.14, and Stroop interference decreased by 36 milliseconds. The physiological cost included a reduction in heart-rate variability (root mean square of successive differences or RMSSD) from 42±12 to 28±8 ms and a two-hour shift in daily cortisol rhythms. Cluster analysis revealed three behavioral profiles. The strategic group scored 8.7 out of 10 while completing 40% of the material. Predictive models identified academic failure with 82.3% accuracy 21 days in advance, showing 76% sensitivity and 81% specificity. Individualized interventions triggered by physiological indicators increased academic performance by 24% and reduced stress by 38%. The return on investment was 4.2 to 1. The findings support the integration of early-warning algorithms into educational systems.

  • Open Access

    Telecommunication project methods as an effective tool in modern education

    by Marina Lebedeva, Vladimir Beketov, Marina Taranova

    This article is devoted to the study of the problem of insufficient involvement of philology students in the educational process, which negatively affects their academic performance. To solve this problem, a telecommunication project was developed and implemented to improve learning efficiency and student engagement. The research was based on a pilot project with one group, and survey methods were also utilized to measure the level of student engagement in the learning process. Statistical analysis results indicate a noticeable improvement in students’ academic performance after the implementation of the innovative telecommunication course, with the average score increasing from 75.5 to 80.1, supported by a statistically significant level. Survey data on student engagement demonstrate a high level of positive attitude towards the use of technology in the educational process. The overall trend indicates a positive attitude towards new technologies in education. The practical significance of this article lies in highlighting telecommunication project methods as an effective tool in modern education. Applying the results of this research in educational practice can contribute to the development and implementation of new educational programs based on telecommunication projects.

  • α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study

    by Ludmila Yu. Milovanova, Kirill S. Nezhdanov, Svetlana Yu. Milovanova, Marina V. Lebedeva, Vladimir D. Beketov, Alexey V. Volkov, Elena S. Kamyshova, Aleksandr Yu. Suvorov, Sergey V. Moiseev

    Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract


  • Open Access

    Anemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis

    by Marina V. Markina, Ludmila Yu. Milovanova, Lidia V. Lysenko, Svetlana Yu. Milovanova, Alexey V. Volkov, Vladimir D. Beketov, Marina V. Lebedeva, Kirill S. Nezhdanov, Sergey V. Moiseev

    Aim. To determine biomarkers of anemia of chronic disease (ACD) in patients with glomerulonephritis (GN) in the early stages of CKD, to assess their role as risk factors for cardiovascular complications (CVС). Materials and methods. Seventy nine patients with GN were studied, among them: 40 with primary сhronic GN (CGN), 39 with secondary forms:19 – GN with ANCA-associated systemic vasculitis, 20 – GN with systemic lupus erythematosus (SLE) at early (all I–II) CKD stages. In all patients, the level of serum C-reactive protein (CRP), hepcidin, interferon γ, and the circulating form of protein Klotho (s-Klotho) were determined. When a relative iron deficiency was detected [transferrin iron saturation coefficient (TSAT) 20%], patients were administered parenterally iron [III] sucrose hydroxide complex (Venofer). Results. The frequency of anemia among patients with systemic diseases is 3.2 times higher than among patients with primary CGN. Patients with anemia (group I; n=43) had higher rates of daily proteinuria (p0.001), systolic blood pressure (p0.05), serum levels of interferon γ (p0.001) and hepcidin (p0.001) and lower values of eGFR (p0.05) than patients without anemia (group II; n=36). A strong inverse correlation was noted between the level of hepcidin and the content of iron in serum (r=-0.856; p0.001), between the level of hemoglobin and the level of interferon γ (r=-0.447; p0.05), hepcidin (r=-0.459; p0.05) and CRP (r=-0.453; p0.05). A significant inverse correlation was found between the level of hemoglobin and CVC risk factors – the value of systolic blood pressure (r=-0.512; p0.05) and the mass index of the left ventricular myocardium (r=-0.619; p0.01). At the same time, the contribution of 2 from 6 analyzed factors, hepcidin and eGFR, to the development of ACD was 92.5%, of which 86.6% accounted for hepcidin. A strong direct correlation was also found between a decrease in hemoglobin level and a decrease in the level of s-Klotho protein (r=0.645; p0.001), a decrease in the level of s-Klotho and an increase in the level of serum hepcidin (r=-0.541; p0.05). The leading value of anemia (beta -0,29; p=0,04) and depression of the s-Klotho level (beta -0,44; p=0,02) as independent cardiovascular risk factors in this group of patients was confirmed by multivariate analysis. In patients with identified deficiency of iron (n=40), after 3–4 weeks of intravenous administration of venofer, the target level of hemoglobin (Нb120 g/l) and transferrin saturation with iron (TSAT20%) were achieved. Conclusion. Among the biomarkers of ACD in patients with immunoinflammatory diseases of the kidneys (primary and secondary СGN), the increase in the serum level of hepcidin is greatest importance. The concomitant to anemia decrease in s-Klotho is a leading risk factor for CVС in CKD. Early correction of ACD with iron supplements makes it possible to achieve target levels of Hb and TSAT and have subsequently a positive effect on the production of s-Klotho and the severity of left ventricular hypertrophia.


  • Open Access

    Diagnostic and treatment difficulties in kidney damage in the patient with generalized sarcoidosis during COVID-19. Case report

    by Marina V. Lebedeva, Natalia V. Chebotareva, Vladimir D. Beketov

    The presented clinical observation reflects the difficulties of differential diagnosis of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection. The differential circle included interstitial nephritis as an exacerbation of the underlying disease, acute drug-induced kidney injury, acute glomerulonephritis. Nephrobiopsy confirmed the diagnosis of acute sarcoid tubulointerstitial nephritis with acute tubular necrosis. Timely administration of corticosteroids led to the control of the sarcoidosis process, restoration of kidney function.


  • Open Access

    Soy protein as part of a low-protein diet is a new direction in cardio- and nephroprotection in patients with 3B–4 stages of chronic kidney disease: prospective, randomized, controlled clinical study

    by Ludmila Yu. Milovanova, Marina V. Taranova, Alexey V. Volkov, Svetlana Yu. Milovanova, Vladimir D. Beketov

    Background. It has been established that the use of a low-protein diet (LPD) in combination with ketoanalogues (KA) of essential amino acids can contribute to cardio- and nephroprotection in chronic kidney disease (CKD). Moreover, it has been shown that replacing part of the animal protein with soy protein (SP) in the diet contributed to more pronounced nephro- and cardioprotection in CKD, however, the data, available in the literature, are mainly represented by experimental studies. Aim. To compare the effects of 2 types of diets on the main parameters of nephro- and cardioprotection in patients with CKD. Materials and methods. We have conducted a prospective, randomized, controlled clinical study which included 85 patients with 3B4 stages of CKD, compliant to LPD (0.6 g of protein/kg body weight) + KA (1 tablet/5 kg body weight). 43 patients (Group 1) received LPD with replacing animal protein with soy (60% soy protein + 40% another vegetable proteins) + KA, and 42 patients (control group, Group 2) received LPD (60% animal protein + 40% vegetable protein) + KA, within 12 months. Results. The dietary substitution of animal protein with SP to a greater extent delayed the decrease in glomerular filtration rate (-5.9% vs -13.3%; p=0.048), the increase in left ventricular hypertrophy (+4.7% vs +12.3%; p=0.042), as well as the increase in central systolic blood pressure (+2.6% vs +13.0%; p=0.021), augmentation index (+7.6% vs +23.3%; p=0.010), slowed down the decrease in lean body mass in men (+0.9% vs -11.2%; p=0.017) and women (-1.8% vs -10.3%; p=0.024), increase in phosphorus (-10.3% vs +13.0%; p=0.029), cholesterol (-10.7% vs -3.4%; p=0.047) and urea (+6.3% vs +19.6%; p=0.035) serum levels. Conclusion. The use of LPD with substitution of animal protein with soy protein + KA provides a more pronounced effect on nephro- and cardioprotection as well as maintenance of nutritional status, than conventional LPD + KA in patients with 3B4 stages of CKD.


  • Biomarkers of heart and vascular lesions in the framework of mineral and bone disorders in chronic kidney disease, correction possibilities

    by L. Yu. Milovanova, V. D. Beketov, S. Yu. Milovanova, M. V. Taranova, A. A. Filippova, A. I. Pasechnik

    Сardiovascular disease (СVD) is the most common complication of chronic kidney disease (СKD). In patients with the earlier stages of CKD, the risk of death from CVD greatly exceeds the risk of progression to end-stage renal disease. In recent years, accumulated data suggest that chronic kidney disease — mineral and bone disorders (CKD-MBD) are strongly associated with cardiovascular events and mortality. Among cardiovascular damage in CKD, both, the progressive cardiac remodeling and vascular calcifi cation, contribute immensely, and lead to an urgently high cardiovascular mortality in patients with CKD. Clarifi cation of CKD progression mechanisms and possible early markers of CVD has led to interest in studying the identifi ed factors such as fi broblast growth factor-23 (FGF-23), Klotho and sclerostin in recent years. Results of studies show that disorders in the system of FGF-23–Klotho–sclerostin correlate with the frequency and severity of hypertension, cardiac remodeling, vascular calcifi cation, anaemia, malnutrition, infl ammation, and strongly aggravate cardiovascular risk in CKD. This review represents an analysis of the available data showing the potential association of СVD with established (phosphate, parathyroid hormone (PTH), Vitamin D) and newer (FGF-23, Klotho, sclerostin) СKD-MBD biomarkers. In addition, it has been shown that renoprotective therapy, including renin-angiotensin blockers, low-protein diet with amino/keto acid supplementation, phosphate binders, erythropoiesis stimulators, vitamin D metabolites used to reach the target levels of blood pressure, serum phosphorus, haemoglobin, PTH and nutritional status disorders, can aff ect CKD-MBD biomarkers and reduce the risk of cardiovascular events in CKD patients.


  • Cardiac and vessels remodeling as a result of FGF-23/Klotho factors imbalance in chronic kidney disease patients

    by Milovanova L.YU. Milovanova, Taranova M.V. Taranova, Milovanova S.YU. Milovanova, Kozlov V.V. Kozlov, Beketov V.D. Beketov, Volkov A.V. Volkov, Pasechnik A.I. Pasechnik, Moiseev S.V. Moiseev, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University, M.V. Lomonosov Moscow State University


  • Open Access

    Effect of vitamin D receptor activators on serum Klotho levels in 3b–4 stages chronic кidney disease patients: a prospective randomized study

    by Ludmila Yu. Milovanova, Vladimir D. Beketov, Svetlana Yu. Milovanova, Marina V. Taranova, Vasilii V. Kozlov, Anastasiia I. Pasechnik, Vladimir A. Reshetnikov, Tatiana V. Androsova, Mikhail V. Kalashnikov

    Background. High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD. Aim. To evaluate the impact of vitamin D receptor activators (VDRA) on Klotho serum levels in CKD 3b4 stages patients. Materials and methods. Study included 90 CKD 3b4 stages patients who had elevated serum levels of parathyroid hormone (PTH). From them, 47 patients (group 1) started to treat with the selective VDRA (zemplar 1 mcg/day), and 43 patients (group 2) started to treat with non-selective VDRA (alfacalcidol 0.25 mcg/day). At baseline and after 12 months we conducted routine examination, serum Klotho measurement, and broad cardiovascular examination. Results. The patients who managed to maintain a target serum PTH level, had higher Klotho serum level (p=0.037) at the end of the study. Patients who used selective VDRA significantly more often reached the target PTH level (p=0.032), had higher serum Klotho levels (p=0.037), and glomerular filtration rate (eGFR) level (p=0.048) than patients who used non-selective VDRA. In addition, patients treated with alfacalcidol more than 6 months, more often had hypercalcemia (p=0.047) and hyperphosphatemia (p=0.035). Group 2 showed higher: pulse wave velocity (p=0.051), left ventricular myocardial mass index (p=0.033), and more advanced heart valve calcification (p=0.038). Conclusion. Successful parathyroid hormone level control with vitamin D receptor activators was associated with higher serum Klotho, selective agents having shown greater effect. Long-term treatment with selective vitamin D receptor activators may contribute to cardiovascular calcification prevention by modifying Klotho levels.


  • ALGORITHMS FOR DIAGNOSIS AND THERAPY MENTAL DISORDERS IN GENERAL MEDICAL PRACTICE

    by Sechenov University, Beatrice Volel, Dmitry Petelin, Dmitry Romanov, Evgeniya Voronova, Philipp Kopylov, Vladimir Beketov

    This tutorial is devoted to diagnostic algorithms and curation of the main forms of mental pathology encountered in the practice of therapists and general practitioners. Presented modern scientific and practical information concerning clinical manifestations of depression, anxiety and somatoform disorders, chronic fatigue syndrome, adjustment disorders and chronic delusional disorders in the general medical network. Algorithms for the treatment of the described mental disorders are outlined in the form of visual flowcharts, which increases the availability of material for practical doctor. Significant emphasis is placed on the description of situations in which the patient must be referred to a psychiatrist for consultation. Special attention is paid to the legislative framework for assistance patients with borderline psychiatric disorders in the primary medical network. This training manual is intended for general practitioners and general practitioners. Can be used as educational benefits in the process of continuous postgraduate professional education of doctors.